OncLive TV

Peter Riedell, MD, discussed the long-term efficacy of tisagenlecleucel in the third-line setting in patients with relapsed/refractory follicular lymphoma.

Kenneth Jin Chang Lim, MBBS, discusses the failure of dexamethasone to reduce rates of neurotoxicity in myeloma with high ALC after CAR T-cell therapy.

Yue Wei, PhD, discusses using single-cell sequencing and patient data to validate HMA effects on megakaryocyte maturation in MDS.

Robert Neff, MD, highlights the role of oncology-led advocacy in improving screening uptake in cervical cancer.

Sagar Lonial, MD, FACP, FASCO, discusses the potential role of CELMoD-based combination approaches in newly diagnosed, transplant-ineligible multiple myeloma.

Mabel Mardones, MD, discusses how Dato-DXd and sacituzumab govitecan may affect first-line treatment for metastatic triple-negative breast cancer.

Louis Potters, MD, FASTRO, FABS, FACR, discusses the meaning of World Cancer Day and highlights the importance of early detection and screening.

Alexander B. Olawaiye, MD, discusses updated OS data from the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in PROC.

Ryan D. Chow, MD, discusses real-world data showing that upfront enfortumab vedotin dose reduction can improve tolerability without affecting survival.

David Rimm, MD, PhD, discusses the strategic sequencing of ADCs in breast cancer, asserting that these agents should be classified as targeted therapies.

Joyce O’Shaughnessy, MD, discusses the rationale for the ongoing ELEGANT trial of elacestrant in high-risk, ER-positive, HER2-negative early breast cancer.

Nicholas James Short, MD, discusses the roles of molecular and genetic testing in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Rahul Banerjee, MD, FACP, discusses the potential long-term role of CELMoDs in the multiple myeloma treatment paradigm.

William A. Hall, MD, discusses the rationale of the phase 2/3 Janus Rectal Cancer Trial.

Kanwal P.S. Raghav, MBBS, MD, discusses standards for data interpretation in clinical trials involving ctDNA testing in CRC.

Xiuning Le, MD, PhD, discusses the mechanism of action of sevabertinib in HER2-mutated NSCLC.

Raji Shameem, MD, discusses first-line treatment planning for pancreatic adenocarcinoma including clinical trial eligibility alongside standard chemotherapy options.

Kristen Spencer, DO, discusses first-line regimen selection in metastatic pancreatic adenocarcinoma.

Yue Wei, PhD, discusses how HMAs promote late-stage megakaryocyte maturation and platelet production in MDS mouse models.

Robert Neff, MD, discusses the potential benefits of self-collected HPV testing and the challenges of implementing this screening method in practice.

Marc J. Braunstein, MD, PhD, discusses the clinical implications of the FDA approval of subcutaneous daratumumab with VRd for newly diagnosed multiple myeloma, ineligible ASCT.

Guillermo Garcia-Manero, MD, discusses the rationale and design of the GLORA-4 trial evaluating lisaftoclax plus azacitidine in high-risk MDS.

Aditya Bardia, MD, MPH, FASCO, discussed data from the lidERA trial of giredestrant vs SOC endocrine therapy in ER-positive, HER2-negative breast cancer.

Natalie Callander, MD, discusses the role of ALC monitoring in the management of relapsed/refractory multiple myeloma following CAR T-cell therapy.

Enriqueta Felip, MD, PhD, discusses key efficacy data from the MARIPOSA trial and its implications.

William A. Hall, MD, discusses the need for more precise radiation therapy in rectal cancer.

Enriqueta Felip, MD, PhD, discusses EGFR-mutated non-small cell lung cancer and how to approach it from multiple angles.

Kevin Kalinsky, MD, MS, FASCO, discusses safety and quality of life data from ASCENT-04 in PD-L1–positive metastatic TNBC.

Komal Jhaveri, MD, FACP, discusses lessons learned from the negative phase 3 ASCENT-07 trial in hormone receptor–positive, HER2-negative breast cancer.

Shaji Kumar, MD, shares phase 1 data from the CAMMA 1 trial evaluating cevostamab alone or in different combinations in relapsed/refractory myeloma.